Announcement on Daily Related Party Transactions
Filed with SSE · · 13 pages · Chinese
China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix
Earlier from China Resources Double-Crane Pharmaceutical
- Announcement on Notice to Creditors on Repurchasing and Canceling Some Restricted Stocks to Reduce Registered Capital
- Announcement on Obtaining Approval Notice for Drug Clinical Trials for DC6001 Tablets by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
- Notice on Convening the 3rd Extraordinary General Meeting in 2025
- Announcement on the Inclusion of the Company’s Drug in the National Medical Insurance Catalog
- Announcement on Wholly-owned Sub-subsidiary Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Passing GMP Compliance Inspection
Later from China Resources Double-Crane Pharmaceutical
- Announcement on Hydroxocobalamin Injection Obtaining Notice of Approval for Drug Clinical Trial
- Announcement on Completion of Fund Filing for the Establishment of Double-Crane Industry Fund
- Announcement on Completion of Fund Filing for Participating in the Establishment of Double-Crane Pharmaceutical Industry Investment Fund Phase II
- Announcement on Wholly-owned Subsidiary Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd. Passing GMP Compliance Inspection
- Announcement on Obtaining Notice of Approval for Drug Supplementary Application for Pediatric Compound Amino Acid Injection (19AA-I-SF)
Follow China Resources Double-Crane Pharmaceutical into a list and get an email when it puts out news.
Follow China Resources Double-Crane Pharmaceutical